Market Cap : 41.77 B | Enterprise Value : 43.49 B | PE Ratio : 14.77 | PB Ratio : 3.27 |
---|
BIIB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIIB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2023-01-28), the stock price of Biogen is $290.08. Biogen's graham number for the quarter that ended in Sep. 2022 was $124.18. Therefore, Biogen's Price to Graham Number ratio for today is 2.34.
The historical rank and industry rank for Biogen's Graham Number or its related term are showing as below:
During the past 13 years, the highest Price to Graham Number ratio of Biogen was 19.73. The lowest was 0.43. And the median was 3.18.
BIIB's Price-to-Graham-Number is ranked worse thanGraham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
The historical data trend for Biogen's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Biogen's Graham Number, along with its competitors' market caps and Graham Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Biogen's Graham Number distribution charts can be found below:
* The bar in red indicates where Biogen's Graham Number falls in comparison to its industry or sector. The grey bar indicates the Graham Number's extreme value range as defined by GuruFocus.
Graham Number is a concept based on Ben Graham's conservative valuation of companies.
Biogen's Graham Number for the fiscal year that ended in Dec. 2021 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI) |
= | sqrt of (22.5 | * | 19.822 | * | 10.4) |
= | 68.11 |
Biogen's Graham Number for the quarter that ended in Sep. 2022 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI (TTM)) |
= | sqrt of (22.5 | * | 34.899 | * | 19.64) |
= | 124.18 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Biogen's Price to Graham number Ratio for today is calculated as
Price to Graham number | = | Share Price (Today) | / | Graham number (Q: Sep. 2022 ) |
= | 290.08 | / | 124.18 | |
= | 2.34 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Thank you for viewing the detailed overview of Biogen's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.
Murphy Nicole | officer: Head of Pharm Ops and Tech | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Izzar Rachid | officer: Head of Alzheimer's Disease | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Jones William D /ca/ | director | |
Freire Maria C | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC 26 NORTH EUCLID AVENUE PASADENA CA 91101 |
Mcdonnell Michael R | officer: EVP, Chief Financial Officer | C/O IQVIA HOLDINGS INC. 83 WOOSTER HEIGHTS ROAD DANBURY CT 06810 |
Galdes Alphonse | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Hawkins William A | director | MEDTRONIC INC 710 MEDTRONIC PKWY, MS LC310 MINNEAPOLIS MN 55432-5604 |
Mantas Jesus B | director | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Kramer Robin | officer: VP, Chief Accounting Officer | 999 VANDERBILT BEACH ROAD 3RD FLOOR NAPLES FL 34109 |
Karp Daniel | officer: EVP, Corporate Development | 225 BINNEY STREET CAMBRIDGE MA 02142 |
Capello Jeffrey D | officer: EVP & Chief Financial Officer | BOSTON SCIENTIFIC CORPORATION ONE BOSTON SCIENTIFIC PLACE NATICK MA 01760 |
Guindo Chirfi | officer: EVP Glob. Mkt Acc & Cust Innov | C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Gregory Ginger | officer: EVP, Human Resources | C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Kress Jean-paul | officer: EVP Pres Int'l & Global Hd GTO | 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 |
Mckenzie Paul | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocusNews 04-04-2022
By PRNewswire 03-22-2022
By GuruFocusNews 03-28-2022
By PRNewswire 04-04-2022
By GuruFocusNews 03-30-2022
By PRNewswire 03-09-2022
By GuruFocusNews 03-17-2022
By PRNewswire 03-23-2022
Other Sources
By Fool 2022-03-22
By tipranks.com 2022-03-07
By Zacks 2022-02-08
By Zacks 2022-03-29
By Zacks 2022-03-29
By Zacks 2022-04-04
By Zacks 2022-03-21
By Zacks 2022-03-14
By Zacks 2022-02-24
By Zacks 2022-03-10
By Zacks 2022-02-09
By Zacks 2022-03-30
By Zacks 2022-04-04
By Fool 2022-02-19